Clinical Trials for People with Suboptimal Immune Reconstitution Despite HIV Suppression

Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age. Individuals in this situation still experience a benefit from ART in terms of a greatly reduced risk of opportunistic infections, illness and death, but their risk of these outcomes is higher than among people with greater CD4 T cell gains (for additional background see the webinar hosted by TAG on November 29, 2017 and our March 2018 Issue Brief).

A number of clinical trials are investigating approaches that might boost CD4 T cell recovery in individuals whose CD4 T cell counts remain relatively low despite viral load suppression. The purpose of this page is to provide a resource listing of these clinical trials, which will be updated on an ongoing basis.

Complete information on the trials is available from clinicaltrials.gov by clicking on the study title link.

The Role of Probiotics in HIV Patients With Immunological Non-Responder (PIONIR)
HIV Clinic, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
ART for >/= 6 months, CD4 cell count 200-410, viral load <34 copies/mL

A Single Dose of Pembrolizumab in HIV-Infected People
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
ART for >/= 12 months, CD4 cell count 100-350, viral load <40 copies/mL for >/= 12 month (single blip >40 copies/mL but <500 copies/mL allowed)

Rice Bran Supplementation in Treated HIV Infection (BRM4)
Rand Schrader Health and Research Clinic, Los Angeles, California, United States
ART for >24 weeks, CD4 cell count 100-350, viral load <50 copies/mL

Pyridostigmine as Immunomodulator in People Living With HIV (closed to enrollment)
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán     
Tlalpan, Ciudad de México, Mexico
Stable ART for at least six months, at least two undetectable viral load determinations in the previous six months

Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial (LIFE-HIV) (closed to enrollment)
UCSF, San Francisco, California, United States
NIH Clinical Center, Bethesda, Maryland, United States
Allina Health, Minneapolis, Minnesota, United States
Hennepin County Medical Center, Minneapolis, Minnesota, United States
ART for >2 years, CD4 T cell count <600, viral load <200 copies/mL

Probiotic VSL#3 for Inflammation and Translocation in HIV II (PROOV IT II)
Maple Leaf Medical Clinic & Toronto General Hospital, Toronto, Ontario, Canada
ART for >2 years, CD4 T cell count <350 for last 2 years, viral load <50 copies/mL for the past 2 years (1 viral blip over 500 copies/ml permitted in the past year)

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV (closed to enrollment)
University of Minnesota, Division of Infectious Diseases, Minneapolis, Minnesota, United States
ART for >1 year, CD4 T cell count 200-600, viral load <50 copies/mL

Safety and Efficacy of Allogenic Adoptive Cell Therapy for Immune Reconstitution in Chronic HIV-1 Infected Patients
Beijing 302 Hospital, Beijing, China
ART for >2 years, CD4 T cell count <250 but >50, viral load <50 copies/mL